MAINE CANCER REGISTRY ICD-10-CM CASEFINDING CODE LISTS FOR REPORTABLE TUMORS

(EFFECTIVE DATE 10/1/2020-9/30/2021)

|  |  |
| --- | --- |
| **MCR Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors**  **(Effective 10/1/2019-9/30/2020)** | |
| **ICD-10-CM Code** | **Explanation of Code** |
| C00.\_-C43.\_, C4A.\_,  C45.\_-C48.\_, C49.\_-C96.\_ | Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified sites) and certain specified histologies |
| C44.00, C44.09 | Unspecified/other malignant neoplasm of skin of lip |
| C44.10\_, C44.19­\_ | Unspecified/other malignant neoplasm of skin of eyelid |
| C44.13\_ | Sebaceous cell carcinoma of skin of eyelid, including canthus  Note: Effective 10/1/2018 |
| C44.20\_, C44.29\_ | Unspecified/other malignant neoplasm of skin of ear and external auricular canal |
| C44.30\_, C44.39\_ | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face |
| C44.40, C44.49 | Unspecified/other malignant neoplasm of skin of scalp and neck |
| C44.50\_, C44.59\_ | Unspecified/other malignant neoplasm of skin of trunk |
| C44.60\_, C44.69\_ | Unspecified/other malignant neoplasm of skin of upper limb, including shoulder |
| C44.70\_, C44.79\_ | Unspecified/other malignant neoplasm of skin of lower limb, including hip |
| C44.80, C44.89 | Unspecified/other malignant neoplasm of skin of overlapping sites of skin |
| C44.90, C44.99 | Unspecified/other malignant neoplasm of skin of unspecified sites of skin |
| C49.A\_ | Gastrointestinal Stromal Tumors  Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS |
| D00.\_-D09.\_ | In-situ neoplasms  (Note: Carcinoma in situ of the cervix [CIN III-8077/2] and Prostatic Intraepithelial Carcinoma [PIN III-8148/2] are not reportable). |
| D18.02 | Hemangioma of intracranial structures and any site |
| D32.\_ | Benign neoplasm of meninges (cerebral, spinal and unspecified) |
| D33.\_ | Benign neoplasm of brain and other parts of central nervous system |
| D35.2-D35.4 | Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland |
| D42.\_, D43.\_ | Neoplasm of uncertain or unknown behavior of meninges, brain, CNS |
| D44.3-D44.5 | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland |
| D45 | Polycythemia vera (9950/3)  *ICD-10-CM coding instruction note: excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)* |
| D46.\_ | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992) |
| D47.02 | Systemic mastocytosis |
| **ICD-10 Code** | **Explanation of Code** |
| D47.1 | Chronic myeloproliferative disease (9963/3, 9975/3).  *ICD-10-CM coding instruction note: Excludes the following:  Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2\_)*  *Chronic myeloid leukemia BCR/ABL-positive (C92.1\_)*  *Myelofibrosis and secondary myelofibrosis (D75.81)*  *Myelophthisic anemia and myelophthisis (D61.82)* |
| D47.3 | Essential (hemorrhagic) thrombocythemia (9962/3)  *Includes essential thrombocytosis, idiopathic hemorrhagic thrombocythemia* |
| D47.4 | Osteomyelofibrosis (9961/3)  *Includes: Chronic idiopathic myelofibrosis*  *Myelofibrosis (idiopathic) (with myeloid metaplasia)*  *Myelosclerosis (megakaryocytic with myeloid metaplasia)*  *Secondary myelofibrosis in myeloproliferative disease* |
| D47.9 | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3) |
| D47.Z\_ | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3) |
| D49.6, D49.7 | Neoplasm of unspecified behavior of brain, endocrine glands and other CNS |
| D72.110 | Idiopathic hypereosinophilic syndrome [HES] |
| D72.111 | Lymphocytic Variant Hypereosinophilic syndrome [LHES] |
| D72.118 | Other hypereosinophilic syndrome |
| D72.119 | Hypereosinophilic syndrome [HES], unspecified |
| J91.0 | Malignant pleural effusion  *ICD-10-CM Coding instruction: Code first underlying neoplasm* |
| R18.0 | Malignant ascites  *ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56.\_), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)* |
| R85.614 | Cytologic evidence of malignancy on smear of anus |
| R87.614 | Cytologic evidence of malignancy on smear of cervix |
| R87.624 | Cytologic evidence of malignancy on smear of vagina |

**Cases with these codes should be screened as registry time allows. Experience in registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases.**

|  |  |  |
| --- | --- | --- |
| **MCR Supplemental List ICD-10-CM Codes (Effective Dates 10/1/2018-9/30/2019)** | | |
| **ICD-10 Code** | | **Explanation Of Code** |
| B20 | | Human immunodeficiency virus (HIV) disease with other diseases |
| B97.33, B97.34, B97.35 | | Human T-cell lymphotrophic virus (type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere |
| B97.7 | | Papillomavirus as the cause of diseases classified elsewhere |
| C44.01, C44.02 | | Basal and squamous cell carcinoma of skin of lip |
| D3A.\_ | | Benign carcinoid tumors |
| D10.\_- D31.\_, D34, D35.0, D35.1, D35.5-D35.9, D36.\_ | | Benign neoplasms (see “must collect” list for reportable benign neoplasms).  *Note: Screen for incorrectly coded malignancies or reportable by agreement tumors*  *Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473 of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. Registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported.* |
| D37.\_- D41.\_ | | Neoplasms of uncertain or unknown behavior (see “must collect” list for reportable neoplasms of uncertain or unknown behavior).  *Note: Screen for incorrectly coded malignancies or reportable by agreement tumors* |
| D44.0-D44.2, D44.6-D44.9 | | Neoplasm of uncertain or unknown behavior of other endocrine glands (see “must collect” list for D44.3-D44.5).  *Note: Screen for incorrectly coded malignancies or reportable by agreement tumors* |
| D47.01 | | Cutaneous mastocytosis (9740/1) |
| D47.09 | | Other mast cell neoplasms of uncertain behavior |
| D47.2 | | Monoclonal gammopathy  Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia |
| D47.Z2 | | Castleman disease |
| D48.\_ | | Neoplasm of uncertain behavior of other and unspecified sites |
| D49.0-D49.9 | | Neoplasm of unspecified behavior (except for D49.6 and D49.7) |
| D61.1 | | Drug-induced aplastic anemia (also known as “aplastic anemia due to antineoplastic chemotherapy”)  *ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug.* |
| D61.810 | | Antineoplastic chemotherapy induced pancytopenia |
| D61.82 | | Myelophthisis  *ICD-10-CM Coding Instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50.\_)* |
| D63.0 | | Anemia in neoplastic disease  *ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)* |
| **ICD-10 Code** | | **Explanation Of Code** |
| D64.81 | | | Anemia due to antineoplastic chemotherapy |
| D69.49, D69.59,  D69.6 | | | Other thrombocytopenia  Note: Screen for incorrectly coded thrombocythemia |
| D70.1 | | | Agranulocytosis secondary to cancer chemotherapy  *ICD-10-CM Coding instruction: code also underlying neoplasm* |
| D75.81 | | | Myelofibrosis (note: this is not primary myelofibrosis [9961/3])  *ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of the breast (C50.\_)* |
| D76.\_ | | | Other specified diseases w/ participation of lymphoreticular and reticulohistiocytic tissue |
| D89.0, D89.1 | | | Other disorders involving the immune mechanism, not elsewhere classified  Note: Review for miscodes |
| D89.4\_ | | | Mast cell activation syndrome and related disorders. |
| E08 | | | Diabetes mellitus due to underlying condition  *ICD-10-CM Coding instruction note: Code the first underlying condition, such as: malignant neoplasm (C00-C96)* |
| E31.2\_ | | | Multiple endocrine neoplasia [MEN] syndromes  *ICD-10-CM Coding Instruction: Code also any associated malignancies and other conditions associated with the syndromes* |
| E34.0 | | | Carcinoid syndrome  *ICD-10-CM Coding Instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor* |
| E83.52 | | | Hypercalcemia |
| E88.09 | | | Other disorders of plasma-protein metabolism, not elsewhere classified |
| E88.3 | | | Tumor lysis syndrome (following antineoplastic chemotherapy) |
| G13.0 | | | Paraneoplastic neuromyopathy and neuropathy  *ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)* |
| G13.1 | | | Other systemic atrophy primarily affecting central nervous system in neoplastic disease  *ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)* |
| G32.8\_ | | | Other specified degenerative disorders of nervous system in diseases classified elsewhere  *ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to neoplasm) (C00-D49)* |
| G53 | | | Cranial nerve disorders in diseases classified elsewhere  *Note: Code first underlying neoplasm (C00-D49)* |
| G55 | | | Nerve root and plexus compressions in diseases classified elsewhere.  *ICD-10-CM Coding instruction note: Code also underlying disease, such as neoplasm (C00-D49)* |
| G63 | | | Polyneuropathy in diseases classified elsewhere.  *ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49)* |
| **ICD-10 Code** | **Explanation Of Code** | |
| G73.1 | | | Lambert-Eaton syndrome in neoplastic disease  *ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)* |
| G89.3 | | | Neoplasm related pain (acute)(chronic) |
| G99.2 | | | Myelopathy in diseases classified elsewhere.  *ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49)* |
| H47.42 | | | Disorders of optic chiasm in (due to) neoplasm  *ICD-10-CM Coding instruction: Code also underlying condition* |
| H47.52\_ | | | Disorders of visual pathways in (due to) neoplasm.  *ICD-10-CM Coding instruction: Code also underlying condition* |
| H47.63\_ | | | Disorders of visual cortex in (due to) neoplasm  *ICD-10-CM Coding instruction: Code also underlying condition* |
| J34.81 | | | Nasal mucositis (ulcerative) |
| J93.12 | | | Secondary spontaneous pneumothorax  *ICD-10-CM Coding instruction: Code first underlying condition, such as: malignant neoplasm of bronchus and lung (C34.\_); secondary malignant neoplasm of lung (C78.0\_)* |
| K12.31 | | | Oral mucositis (ulcerative) due to antineoplastic therapy |
| K12.33 | | | Oral mucositis (ulcerative) due to radiation |
| K22.711 | | | Barrett’s esophagus with high grade dysplasia |
| K62.7 | | | Radiation proctitis |
| K92.81 | | | Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy) |
| M36.0 | | | Dermato(poly)myositis in neoplastic disease  *ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)* |
| M36.1 | | | Arthropathy in neoplastic disease  *ICD-10-CM Coding instruction: Code first underlying neoplasm, such as:*  *Leukemia (C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0)* |
| M84.5\_ | | | Pathologic fracture in neoplastic disease  *ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49)* |
| M90.6\_ | | | Osteitis deformans in neoplastic disease  *ICD-10-CM Coding instruction: Code first the neoplasm (C40.\_, C41.\_)* |
| N76.81 | | | Mucositis (ulcerative) of vagina and vulva |
| O01.\_ | | | Hydatidiform mole  *Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3) with a malignancy code in the C00-C97 range* |
| O9A.1\_ | | | Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96).  *ICD-10-CM Coding Instruction: Use additional code to identify neoplasm* |
| Q85.0\_ | | | Neurofibromatosis (nonmalignant) (9540/1)  *Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable.* |
| R53.0 | | | Neoplastic (malignant) related fatigue  ICD-10-CM Coding instruction: Code first associated neoplasm |
| R59.\_ | | | Enlarged lymph nodes |
| **ICD-10-CM Code** | **Explanation Of Code** | |
| R85.6\_ | | | Abnormal findings on cytological and histological examination of digestive organs  Note: See “must collect” list for R85.614 |
| R87.61\_, R87.62\_ | | | Abnormal findings on cytological/histological examination of female genital organs  *Note: See “must collect” list for R87.614 and R87.624* |
| R92.\_ | | | Abnormal findings on diagnostic imaging of breast |
| R97.\_ | | | Abnormal tumor markers |
| T38.6\_ | | | Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified |
| T38.8\_, T38.9\_ | | | Poisoning by hormones and their synthetic substitutes |
| T45.1\_ | | | Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs |
| T45.8\_, T45.9\_ | | | Poisoning by primary systemic and hematological agent, unspecified |
| T66 | | | Unspecified effects of radiation |
| T80.1 | | | Vascular complications following infusion, transfusion and therapeutic injection |
| T80.2\_ | | | Infections following infusion, transfusion and therapeutic injection |
| T80.810 | | | Extravasation of vesicant antineoplastic chemotherapy |
| T80.818 | | | Extravasation of other vesicant agent |
| T86.0 | | | Complications of bone marrow transplant  *ICD-10-CM Coding instruction: Use additional code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)* |
| Y63.2 | | | Overdose of radiation given during therapy |
| Y84.2 | | | Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
| Z03.89 | | | Encounter for observation for other suspected diseases and conditions ruled out |
| Z08 | | | Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment).  *ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85.\_)* |
| Z12.\_ | | | Encounter for screening for malignant neoplasms |
| Z13.0 | | | Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism |
| Z15.0 | | | Genetic susceptibility to malignant neoplasm  *ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); use additional code, if applicable, for any personal history of malignant neoplasm (Z85.\_)* |
| **ICD-10 Code** | | **Explanation of Code** | |
| Z17.0, Z17.1 | | | Estrogen receptor positive and negative status  *ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50.\_)* |
| Z40.0\_ | | | Encounter for prophylactic surgery for risk factors related to malignant neoplasms |
| Z42.1 | | | Encounter for breast reconstruction following mastectomy |
| Z48.290 | | | Encounter for aftercare following bone marrow transplant |
| Z48.3 | | | Aftercare following surgery for neoplasm  *ICD-10-CM Coding instruction: Use additional code to identify the neoplasm* |
| Z51.0 | | | Encounter for antineoplastic radiation therapy |
| Z51.1\_ | | | Encounter for antineoplastic chemotherapy and immunotherapy |
| Z51.5, Z51.89 | | | Encounter for palliative care and other specified aftercare |
| Z79.81\_ | | | Long term (current) use of agents affecting estrogen receptors and estrogen levels. *ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50.\_), malignant neoplasm of prostate (C61)* |
| Z85.\_ | | | Personal history of malignant neoplasm  *ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08).* |
| Z86.0\_, Z86.01\_,  Z86.03 | | | Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior |
| Z92.21, Z92.23,  Z92.25. Z92.3 | | | Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation) |
| Z94.81, Z94.84 | | | Bone marrow and stem cell transplant status |